In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues.
In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues.
复制标题
DOI：
10.1007/s10147-006-0618-x
复制
发表时间：
2006-12-01
影响因子：
3.3
通讯作者：
Nakao, Akimasa
中科院分区：
文献类型：
--
作者：
Kodera, Yasuhiro;Ito, Seiji;Nakao, Akimasa
背景：化疗敏感性和耐药试验指导的治疗可能会导致合理的治疗决策。方法：采用组织培养药物反应试验（Histoculturedrugresponsibilityassay，HSP 70）对113例胃癌患者的新鲜原发肿瘤标本进行体外药敏试验。对于最初的45个样品，在含有三种不同浓度紫杉醇的培养基中进行试验。化疗敏感性测试的结果之间的相关性，确定在最佳浓度，和患者的临床病理因素和结果，然后评估所有patients.Results：通过分析最初的45个样本，10 μ g/ml被认为是最佳浓度的紫杉醇进行这项测试。对113个样品中的100个成功地进行了抑制，并且化学敏感性（计算为用抗癌药物处理的肿瘤的光密度相对于仅在培养基中培养的肿瘤的光密度的百分比）在该浓度下广泛分布。化疗敏感性与年龄、性别、临床分期、组织病理学类型和胃癌患者预后无显著相关性。结论：组织培养药物反应试验可用于预测紫杉醇在本研究浓度下的化疗敏感性。该检测方法实际预测生存率的准确性需要通过一项前瞻性临床试验进行验证，该试验涉及在术后辅助治疗中接受紫杉醇治疗的患者。
BACKGROUND: Therapy guided by chemotherapy sensitivity and resistance assays may lead to rational treatment decisions. Paclitaxel, one of several new drugs for gastric carcinoma, has not been extensively evaluated by in vitro chemosensitivity tests.METHODS: Chemosensitivity testing by histoculture drug response assay (HDRA) was performed with fresh specimens of primary tumor from 113 patients with gastric carcinoma. The test was performed in medium containing paclitaxel at three different concentrations for the initial 45 samples. Correlations between the results of chemosensitivity testing, determined at the optimal concentration, and the patients' clinicopathologic factors and outcome were then assessed for all patients.RESULTS: By analyzing the initial 45 samples, 10 microg/ml was considered the optimal concentration of paclitaxel for this test. HDRA was successfully performed for 100 of 113 samples and chemosensitivity, calculated as the percentage of optical density of a tumor treated with anticancer drugs in relation to the optical density of the tumor cultured in the medium only, was distributed widely at this concentration. No significant correlation was observed between chemosensitivity and age, sex, clinical stage, histopathologic type, and outcome of patients with gastric carcinoma.CONCLUSION: A histoculture drug response assay can now be performed to predict the chemosensitivity of paclitaxel at the concentration found in the current study. The accuracy of the assay to actually predict survival needs to be validated by a prospective clinical trial involving patients who have received paclitaxel in the postoperative adjuvant setting.